Every 10-Q that Aurinia Pharmaceuticals Inc (AUPH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AUPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AUPH filings page.
Aurinia Pharmaceuticals Inc. delivered higher profitability for the quarter ended June 30, 2026, driven by growth in LUPKYNIS. Net product sales were $79.4 million in the quarter and $153.0 million year‑to‑date, and diluted earnings per share reached $0.28 for the quarter.
Net income and operating cash flow both increased versus 2025, with cash flows from operating activities of $85.1 million for the first six months. Cash, cash equivalents, restricted cash and investments rose to $443.1 million, even after repurchasing 5.0 million common shares for $74.9 million.
Aurinia advanced its autoimmune pipeline by initiating PRESERVE, a Phase 4 study combining LUPKYNIS with several biologics in lupus nephritis, and by progressing aritinercept in four indications. It also completed an asset acquisition of Kezar Life Sciences, adding cash, in‑process R&D and a contingent value right structure.
Aurinia Pharmaceuticals delivered a stronger Q1 2026, driven by growth in its lupus nephritis drug LUPKYNIS. Total revenue rose to $77.7 million from $62.5 million, as net product sales increased 23% to $73.6 million and collaboration revenue with Otsuka also expanded.
Net income improved to $34.4 million from $23.3 million, with gross margin rising to 92% from 86% as lower low-margin sales to Otsuka reduced cost of revenue. Operating cash flow surged to $32.6 million, up from $1.3 million, reflecting higher profitability and working-capital shifts.
Aurinia ended the quarter with $378.8 million in cash, equivalents, restricted cash and investments, even after repurchasing 2.5 million shares for $36.8 million; cumulative buybacks since February 2024 total 23.1 million shares for $211.0 million. The company signed a definitive agreement to acquire Kezar Life Sciences for $6.955 per share in cash plus a contingent value right, targeting additional autoimmune and oncology assets. Leadership also changed, with Kevin Tang appointed CEO, Ryan Cole COO and Michael Hearne CFO, replacing the prior executive team, which remains as consultants during a transition period.
Aurinia Pharmaceuticals (AUPH) reported stronger Q3 2025 results, led by continued LUPKYNIS growth and lower operating costs. Total revenue was $73.5 million, up from $67.8 million a year ago, with net product sales of $70.6 million. Net income rose to $31.6 million from $14.4 million as SG&A spending declined following 2024 restructuring actions. Gross margin was 89% for the quarter.
Year to date, revenue reached $205.9 million and net income was $76.4 million. Operating cash flow for the nine months was $90.0 million. Cash, cash equivalents, restricted cash and investments were $351.8 million as of September 30, 2025. The company repurchased 12.2 million common shares year to date under its authorized program. Common shares outstanding were 131,840,559 as of November 3, 2025.